Litigation Details for Pharmacyclics LLC v. Alvogen Pine Brook LLC (D. Del. 2019)
✉ Email this page to a colleague
Pharmacyclics LLC v. Alvogen Pine Brook LLC (D. Del. 2019)
| Docket | 1:19-cv-00434 | Date Filed | 2019-03-01 |
| Court | District Court, D. Delaware | Date Terminated | 2021-08-30 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | Christopher J. Burke |
| Parties | PHARMACYCLICS LLC | ||
| Patents | 10,004,746; 10,010,507; 10,016,435; 10,106,548; 10,125,140; 10,213,386; 10,294,231; 10,294,232; 11,058,667; 11,135,192; 6,346,532; 7,342,117; 7,514,444; 7,879,828; 7,982,049; 8,008,309; 8,022,106; 8,101,659; 8,476,284; 8,497,277; 8,563,563; 8,697,711; 8,703,780; 8,735,403; 8,754,090; 8,754,091; 8,796,331; 8,877,938; 8,952,015; 8,957,079; 8,999,999; 9,125,889; 9,181,257; 9,296,753; 9,388,134; 9,517,226; 9,540,382; 9,655,857; 9,713,617; 9,725,455; 9,795,604; 9,801,881; 9,801,883; 9,814,721; 9,937,143 | ||
| Attorneys | Irena Royzman | ||
| Firms | Young, Conaway, Stargatt & Taylor LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Pharmacyclics LLC v. Alvogen Pine Brook LLC
The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , and ⤷ Start Trial .
Details for Pharmacyclics LLC v. Alvogen Pine Brook LLC (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-03-01 | External link to document | |||
| 2019-03-01 | 1 | Complaint | PageID #: 2 Patent”); 9,655,857 (“the ’857 Patent”); 9,725,455 (“the ’455 Patent”); 10,010,507 (“the ’507… United States Patent Nos. 7,514,444 (“the ’444 Patent”); 8,008,309 (“the ’309 Patent”); 8,476,284 (“…(“the ’284 Patent”); 8,497,277 (“the ’277 Patent”); 8,697,711 (“the ’711 Patent”); 8,735,403 (“the ’403…’403 Patent”); 8,754,090 (“the ’090 Patent”); 8,754,091 (“the ’091 Patent”); 8,952,015 (“the ’015 Patent…507 Patent”); 10,106,548 (“the ’548 Patent”); and 10,125,140 (“the ’140 Patent”). | External link to document |
| 2019-03-01 | 1120 | FINAL JUDGMENT Regarding U.S. Patent No. 8,101,659 (see Judgment for further details). Signed by…2019 30 August 2021 1:19-cv-00434 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document | |
| 2019-03-01 | 1137 | Invalidity Contentions for U.S. Patent Nos.11,058,667 and 8,101,659 filed by Nanjing Noratech Pharmaceutical…2019 30 August 2021 1:19-cv-00434 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document | |
| 2019-03-01 | 1143 | PROPOSED Final Judgment Regarding U.S. Patent No. 8,101,659, by Novartis Pharmaceuticals Corporation…2019 30 August 2021 1:19-cv-00434 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document | |
| 2019-03-01 | 1144 | FINAL JUDGMENT Regarding U.S. Patent No. 8,101,659 Pursuant to Federal Rule of Civil Procedure …2019 30 August 2021 1:19-cv-00434 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
